SG-5-00455 overview
SG-5-00455 binds to plasminogen activator inhibitor (PAI)-1/2, blocking the inhibitory effect of PAI-1/2 and ultimately reducing fibrosis and improving mucosal healing.
We set out to address a high unmet need in patients with gastrointestinal disorders by finding a protein(s) expressed by healthy microbiome that induce mucosal repair and developed that protein(s) into a naturally derived, safe and potent therapy to improve outcomes for patients.
Inflamed bowel
SG-5-00455 is an oral capsule containing engineered, live Lactococcus lactis (L. lactis) that constitutively expresses the active, therapeutic protein. Our engineered L.lactis drug delivery system is designed to deliver protein(s) directly to gut mucosal tissue.
Inflamed bowel
Once in the target areas of the digestive tract, the oral capsule dissolves.
Inflamed bowel
SG-5-00455 binds to PAI-1/2, blocking the inhibitory effect of PAI-1/2 resulting in reduction of fibrosis and improved direct mucosal healing (as demonstrated in pre-clinical studies).
Mucosal healing
Direct mucosal healing is an area of active drug discovery driven by key medical interest and need – the next frontier in therapy.
How SG-5-0455 Works
PAI-1/2 as a target
External publications and Second Genome data support that PAI-1 plays a key role in IBD – both in patients and in pre-clinical animal models
PAI-1 augments mucosal damage in colitis
Gerard E Kaiko
Science Translational Medicine
Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice
Jin Imai
Intestinal Research
PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system
Silvio Danese and Alfredo Papa
Eur J Gastroenterol Hepatol 20:826–828 2008